Dipexium Pharmaceuticals Llc (DPRX) 11.57 $DPRX
Dipexium (DPRX) Worth Watching: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:46AM CST
Dipexium (DPRX) was a big mover last session, with shares rising nearly 8% on the day.
LCI: 43.58 (-0.46), DPRX: 11.57 (+0.12), SCMP: 13.93 (-0.13), IG: 8.78 (+0.12)
Dipexium Pharmaceuticals Announces Presentation at Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Mon Nov 17, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference in New York City, on Wednesday, December 10, 2014 at 1:00 p.m. Eastern Time.
DPRX: 11.57 (+0.12)
Dipexium beats by $0.04
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:24AM CST
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
PR Newswire - Wed Nov 12, 8:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today reported its financial results for the third quarter ended September 30, 2014 and provided an update on operational progress.
DPRX: 11.57 (+0.12)
Diabetic Foot Ulcers Therapeutics Pipeline Report H2 2014 - Analysis of 26 Companies & 37 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/b997sg/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Lumosa Therapeutics Co., Ltd. - CoDa Therapeutics, Inc. - Adocia - Plurogen Therapeutics, Inc. - EyeGene, Inc. - Izun Pharmaceuticals Corporation - MacroCure - Royer Biomedical, Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. - Innovaxis - Grupo Praxis Pharmaceutical SA Drug Profiles - pexiganan acetate - DermaPro - trafermin - Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - ON-101 - DSC-127 - CureXcell - Granexin - Vivefoot - ReliDerm-DT - CVBT-141B - CODA-001 - PX-070101 - IZN-6D4 - CSTC-1 - PluroGel N - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - AP-102 - Cyndacel-M - EG-Decorin - STD-06 - Nu-2 - Nu-3 - MT-003 - Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers For more information visit http://www.researchandmarkets.com/research/b9...betic_foot
DSCI: 8.60 (-0.20), DPRX: 11.57 (+0.12), GSK: 42.42 (-0.93), CELGZ: 3.51 (-0.03)
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.33 (+0.08), DPRX: 11.57 (+0.12), GCAP: 8.26 (-0.06)
Dipexium Pharmaceuticals Presents Updated Locilex® Microbiology Data at 54th ICAAC Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborators, today announced updated data from a microbiology study of Locilex® were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Announces Presentation at Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Tue Sep 02, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City, on Wednesday, September 10, 2014 at 3:45 p.m. Eastern Time.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
PR Newswire - Tue Aug 12, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today reported its financial results for the second quarter ended June 30, 2014 and provided an update on operational progress.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Initiates Second of Two Pivotal Phase 3 Clinical Trials of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Mon Jul 21, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the second of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Thu Jul 17, 7:01AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Announces Successful Completion of Phase 1 Skin Irritation Trial of Locilex®
PR Newswire - Thu Jul 17, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced successful completion and initial results of DPX-110, a Phase 1 skin irritation clinical trial of Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum topical antibiotic peptide. Dipexium conducted DPX-110 and the company is conducting DPX-120, a Phase 1 skin sensitization clinical trial, in parallel with two required pivotal Phase 3 clinical trials for Locilex®. The Company's pivotal Phase 3 clinical program is subject to a Special Protocol Assessment (SPA) agreement with FDA.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Jul 16, 9:00AM CDT
What:
DPRX: 11.57 (+0.12), NDAQ: 46.11 (-0.86)
Dipexium Pharmaceuticals, Inc. on Preliminary List of Additions to Russell Microcap® Index
PR Newswire - Mon Jun 23, 9:38AM CDT
Dipexium Pharmaceuticals, Inc. (NasdaqCM: DPRX), today announced it was included in the preliminary list of additions to the Russell Microcap® Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.
DPRX: 11.57 (+0.12)
Dipexium (DPRX) Worth Watching: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:46AM CST
Dipexium (DPRX) was a big mover last session, with shares rising nearly 8% on the day.
LCI: 43.58 (-0.46), DPRX: 11.57 (+0.12), SCMP: 13.93 (-0.13), IG: 8.78 (+0.12)
Dipexium Pharmaceuticals Announces Presentation at Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Mon Nov 17, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference in New York City, on Wednesday, December 10, 2014 at 1:00 p.m. Eastern Time.
DPRX: 11.57 (+0.12)
Dipexium beats by $0.04
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:24AM CST
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
PR Newswire - Wed Nov 12, 8:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today reported its financial results for the third quarter ended September 30, 2014 and provided an update on operational progress.
DPRX: 11.57 (+0.12)
Diabetic Foot Ulcers Therapeutics Pipeline Report H2 2014 - Analysis of 26 Companies & 37 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/b997sg/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Lumosa Therapeutics Co., Ltd. - CoDa Therapeutics, Inc. - Adocia - Plurogen Therapeutics, Inc. - EyeGene, Inc. - Izun Pharmaceuticals Corporation - MacroCure - Royer Biomedical, Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. - Innovaxis - Grupo Praxis Pharmaceutical SA Drug Profiles - pexiganan acetate - DermaPro - trafermin - Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases - ON-101 - DSC-127 - CureXcell - Granexin - Vivefoot - ReliDerm-DT - CVBT-141B - CODA-001 - PX-070101 - IZN-6D4 - CSTC-1 - PluroGel N - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - AP-102 - Cyndacel-M - EG-Decorin - STD-06 - Nu-2 - Nu-3 - MT-003 - Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers For more information visit http://www.researchandmarkets.com/research/b9...betic_foot
DSCI: 8.60 (-0.20), DPRX: 11.57 (+0.12), GSK: 42.42 (-0.93), CELGZ: 3.51 (-0.03)
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.33 (+0.08), DPRX: 11.57 (+0.12), GCAP: 8.26 (-0.06)
Dipexium Pharmaceuticals Presents Updated Locilex® Microbiology Data at 54th ICAAC Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborators, today announced updated data from a microbiology study of Locilex® were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Announces Presentation at Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Tue Sep 02, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced that David P. Luci, President & Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City, on Wednesday, September 10, 2014 at 3:45 p.m. Eastern Time.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
PR Newswire - Tue Aug 12, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today reported its financial results for the second quarter ended June 30, 2014 and provided an update on operational progress.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Initiates Second of Two Pivotal Phase 3 Clinical Trials of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Mon Jul 21, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the second of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Thu Jul 17, 7:01AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals Announces Successful Completion of Phase 1 Skin Irritation Trial of Locilex®
PR Newswire - Thu Jul 17, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced successful completion and initial results of DPX-110, a Phase 1 skin irritation clinical trial of Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum topical antibiotic peptide. Dipexium conducted DPX-110 and the company is conducting DPX-120, a Phase 1 skin sensitization clinical trial, in parallel with two required pivotal Phase 3 clinical trials for Locilex®. The Company's pivotal Phase 3 clinical program is subject to a Special Protocol Assessment (SPA) agreement with FDA.
DPRX: 11.57 (+0.12)
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Jul 16, 9:00AM CDT
What:
DPRX: 11.57 (+0.12), NDAQ: 46.11 (-0.86)
Dipexium Pharmaceuticals, Inc. on Preliminary List of Additions to Russell Microcap® Index
PR Newswire - Mon Jun 23, 9:38AM CDT
Dipexium Pharmaceuticals, Inc. (NasdaqCM: DPRX), today announced it was included in the preliminary list of additions to the Russell Microcap® Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.
DPRX: 11.57 (+0.12)
